Skip to content

Study · Non-randomized trial · 2022

11 results

[Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin.]

Kuznik BI, Shapovalov KG, Smolyakov YN, Lukyanov SA, Tereshkov PP, Kazantseva LS, Linkova NS

Advances in gerontology = Uspekhi gerontologii1 Jan 2022Cited by 1 (Europe PMC)

PMID36169363 (opens in a new tab)PepBankPUB-36169363
Publisher pageAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In middle-aged and elderly patients with severe COVID-19, hospital mortality was 20.6% with Thymalin versus 40.9% with basic therapy.

    In plain wordsIn patients with severe COVID-19, hospital mortality was lower with Thymalin than with basic therapy.

    Peptide
    Thymalin
    Outcome
    DecreaseHospital mortality versus basic therapy
    Study

    n: not reported in source

    Comparator
    Basic therapy
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hospital mortality
    20.6%
    Thymalin group
    Hospital mortality
    40.9%
    basic (standard) therapy group

    Source sentences

    Summary
    Hospital mortality in COVID-19 patients after standard therapy, Tocilizumab and Thymalin application was 40,9; 28,4 and 20,6% accordingly.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  2. 02HumanNon-randomized trialSafety outcome

    In middle-aged and elderly patients with severe COVID-19, hospital mortality was 20.6% with Thymalin versus 28.4% with Tocilizumab.

    In plain wordsIn patients with severe COVID-19, hospital mortality was lower with Thymalin than with Tocilizumab.

    Peptide
    Thymalin
    Outcome
    DecreaseHospital mortality versus Tocilizumab
    Study

    n: not reported in source

    Comparator
    Tocilizumab
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Measurements

    Hospital mortality
    20.6%
    Thymalin group
    Hospital mortality
    28.4%
    Tocilizumab group

    Source sentences

    Summary
    Hospital mortality in COVID-19 patients after standard therapy, Tocilizumab and Thymalin application was 40,9; 28,4 and 20,6% accordingly.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with severe COVID-19, Thymalin increased lymphocyte numbers twofold.

    In plain wordsIn patients with severe COVID-19, Thymalin increased lymphocyte numbers.

    Peptide
    Thymalin
    Outcome
    IncreaseLymphocyte number
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Lymphocyte number fold increase
    2 times
    Thymalin group

    Source sentences

    Summary
    Thymalin increased the number of lymphocytes and monocytes by 2 times, the number of leukocytes - by 1,3 times, the number of platelets in the blood - by 1,5 times.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with severe COVID-19, Thymalin increased monocyte numbers twofold.

    In plain wordsIn patients with severe COVID-19, Thymalin increased monocyte numbers.

    Peptide
    Thymalin
    Outcome
    IncreaseMonocyte number
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Monocyte number fold increase
    2 times
    Thymalin group

    Source sentences

    Summary
    Thymalin increased the number of lymphocytes and monocytes by 2 times, the number of leukocytes - by 1,3 times, the number of platelets in the blood - by 1,5 times.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with severe COVID-19, Thymalin increased leukocyte numbers by 1.3 times.

    In plain wordsIn patients with severe COVID-19, Thymalin increased white blood cell numbers.

    Peptide
    Thymalin
    Outcome
    IncreaseLeukocyte number
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Leukocyte number fold increase
    1.3 times
    Thymalin group

    Source sentences

    Summary
    Thymalin increased the number of lymphocytes and monocytes by 2 times, the number of leukocytes - by 1,3 times, the number of platelets in the blood - by 1,5 times.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with severe COVID-19, Thymalin increased platelet numbers by 1.5 times.

    In plain wordsIn patients with severe COVID-19, Thymalin increased platelet numbers.

    Peptide
    Thymalin
    Outcome
    IncreasePlatelet number
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Platelet number fold increase
    1.5 times
    Thymalin group

    Source sentences

    Summary
    Thymalin increased the number of lymphocytes and monocytes by 2 times, the number of leukocytes - by 1,3 times, the number of platelets in the blood - by 1,5 times.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  7. 07HumanNon-randomized trialEfficacy outcome

    In patients with severe COVID-19, Thymalin decreased the platelet/lymphocyte ratio by 1.4 times.

    In plain wordsIn patients with severe COVID-19, Thymalin reduced the ratio of platelets to lymphocytes.

    Peptide
    Thymalin
    Outcome
    DecreasePlatelet/lymphocyte ratio
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Platelet/lymphocyte ratio fold decrease
    1.4 times
    Thymalin group

    Source sentences

    Summary
    Thymain decreased the platelet/lymphocyte and neutrophil/lymphocyte ratios by 1,4 times and 2 times.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  8. 08HumanNon-randomized trialEfficacy outcome

    In patients with severe COVID-19, Thymalin decreased the neutrophil/lymphocyte ratio twofold.

    In plain wordsIn patients with severe COVID-19, Thymalin reduced the ratio of neutrophils to lymphocytes.

    Peptide
    Thymalin
    Outcome
    DecreaseNeutrophil/lymphocyte ratio
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    Neutrophil/lymphocyte ratio fold decrease
    2 times
    Thymalin group

    Source sentences

    Summary
    Thymain decreased the platelet/lymphocyte and neutrophil/lymphocyte ratios by 1,4 times and 2 times.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  9. 09HumanNon-randomized trialEfficacy outcome

    In patients with severe COVID-19, Thymalin decreased blood fibrinogen by 1.2 times.

    In plain wordsIn patients with severe COVID-19, Thymalin reduced blood fibrinogen.

    Peptide
    Thymalin
    Outcome
    DecreaseBlood fibrinogen
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Blood fibrinogen fold decrease
    1.2 times
    Thymalin group

    Source sentences

    Summary
    The use of Thymalin decreased the level of fibrinogen, lactate dehydrogenase and D-dimer in the blood by 1,2; 1,8 and 1,7 times, respectively.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  10. 10HumanNon-randomized trialEfficacy outcome

    In patients with severe COVID-19, Thymalin decreased blood lactate dehydrogenase by 1.8 times.

    In plain wordsIn patients with severe COVID-19, Thymalin reduced blood lactate dehydrogenase.

    Peptide
    Thymalin
    Outcome
    DecreaseBlood lactate dehydrogenase
    Study

    n: not reported in source

    Outcome group
    Organ injury · Whole body
    Studied dose
    Dose not stated

    Measurements

    Blood lactate dehydrogenase fold decrease
    1.8 times
    Thymalin group

    Source sentences

    Summary
    The use of Thymalin decreased the level of fibrinogen, lactate dehydrogenase and D-dimer in the blood by 1,2; 1,8 and 1,7 times, respectively.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.
  11. 11HumanNon-randomized trialEfficacy outcome

    In patients with severe COVID-19, Thymalin decreased blood D-dimer by 1.7 times.

    In plain wordsIn patients with severe COVID-19, Thymalin reduced blood D-dimer.

    Peptide
    Thymalin
    Outcome
    DecreaseBlood D-dimer
    Study

    n: not reported in source

    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Blood D-dimer fold decrease
    1.7 times
    Thymalin group

    Source sentences

    Summary
    The use of Thymalin decreased the level of fibrinogen, lactate dehydrogenase and D-dimer in the blood by 1,2; 1,8 and 1,7 times, respectively.
    1 context sentence
    Summary · context
    Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.